• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Public Consultation on Inclusion of Human Factors for NMPA Medical Device Registrations

Public Consultation on Inclusion of Human Factors for NMPA Medical Device Registrations

Human Factors
Wednesday, 03 June 2020 / Published in Medical Device

Public Consultation on Inclusion of Human Factors for NMPA Medical Device Registrations

On 21.05.2020, the NMPA (National Medical Products Administration) issued a draft guidance document (Official Chinese Version / Unofficial English Translation by Cisema) seeking input on whether to include human factors/usability engineering (HFE) in China NMPA registration of Class II and Class III medical devices. HFE focuses on the interactions between people and devices, ensuring the hardware and software are safe if used as intended. Applying HFE during product registration would be one method to verify the user interface is safe and effective.

Considering the ethnic differences between China and foreign countries, the draft guidance suggests to conduct HFE tests in China on imported medical devices for confirmation, unless sufficient information can be provided to prove that the differences will have no significant impact. The draft guidance suggests that in most circumstances, clinical trials are insufficient to substitute HFE tests.

The document provides that the following information would need to be submitted in the HFE research report (that would be submitted as part of the NMPA application dossier):

  • Basic information (Device name, model number / spec., intended use and target users)
  • Risk level (High, medium, or low) and supporting materials for justification
  • Core elements (Users, usage scenarios, and user interfaces)
  • HFE design process (Flow chart, detailed content and requirements), and checklist of relevant process standards if any
  • Documentation of user interface requirements or product requirements
  • Risk management and risk control measures to ensure all known errors and residual risks are reduced to acceptable levels
  • Evaluation report based on different HFE methods
  • HFE relationship table (User interface requirements, design, risk management, etc.) for tracing analysis
  • Summary report to determine if the user requirements (safety use and effectiveness) have been met

Please share your opinions with us before the consultation period ends on 26th June, so that we can together submit a strong proposal to the Chinese authorities.

Contact us for our translation of the draft guidance document.

By Jacky Li. Contact Cisema to learn more.

Tagged under: HFE, Human Factors, medical device

What you can read next

New Functions of the Technical Review Consultation Platform
Biocompatibility Testing in China of Medical Devices: Regulatory Update
China Medical Device Standards
December 2021 Regulatory Roundup for Medical Device Mandatory Standards

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.